Clozapine vs Paliperidone palmitate (Invega Trinza)
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Schizophrenia
Shared mechanism: Dopamine D2 and serotonin 5-HT2A receptors (antagonist) · full Schizophrenia pipeline
Clozapine
Marketed by HLS Therapeutics Inc.
NCT00250575 · Phase 3 · completed
The study was open-label, single-arm, and had no placebo or active comparator; all 43 participants received clozapine. Its primary measures focused on hematological tests, blood-related adverse events, and monitoring-system compliance rather than a clinical symptom endpoint, and no results are posted.
Next expected readout: April 2027 · NCT04580134 (registry estimate)
Reported efficacy
Treatment efficacy rate (baseline,0.5 months,1 months, 2 months,4 months , 6 months , 8 months and 12 months); All-cause dropout rate (baseline,0.5 months,1 months, 2 months,4 months , 6 months , 8 months and 12 months): Primary 1, symptomatic response (40% or more PANSS total reduction) in phase 2 among 111 re-randomized nonresponders: clozapine 62.5% (20/32) vs amisulpride 44.7% (17/38) vs olanzapine 31.7% (13/41) (chi-square 6.9; P=.03), met. Primary 2, time to all-cause discontinuation: the paper reports no clear difference between treatment groups, missed. (mixed)
Result source: NCT03510325
Paliperidone palmitate (Invega Trinza)
Marketed by Johnson & Johnson
NCT02713282 · Phase 3 · completed
This was a single-group, open-label study without randomization or a comparator arm, so it could not directly compare the 3-month formulation with placebo or another treatment. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.
Reported efficacy
Number of Participants With Relapse (Up to Day 730); Number of Participants With Treatment-emergent Adverse Events (TEAEs) (Up to Day 730): Number of Participants With Relapse (Up to Day 730): Total Paliperidone Palmitate 6-month (PP6M) 700 or 1000 mg eq. 7/178 (not_applicable)
Result source: NCT04072575
Results for Schizophrenia
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
These assets measured different things. Their trials share no endpoint in common, so no efficacy row can be built. That is a property of the programmes rather than a gap in the record: each asset's own reported endpoints are listed below.
| Key endpoint | Clozapine | Paliperidone palmitate (Invega Trinza) |
|---|---|---|
| PANSS total, change | —Not posted · NCT00649844 | -1.8 vs -1.6vs PP3MNCT03345342 |
| CGI-S, change | —Not posted · NCT00649844 | 0 vs 0vs PP3MNCT033453422 other results
|
| PANSS response | —Not posted · NCT00649844 | —Not posted · NCT02713282 |
| PSP, change | —Not posted · NCT00649844 | 1 vs 1.1vs PP3MNCT033453422 other results
|
| Relapse (% of patients) | —Not posted · NCT00649844 | —Not posted · NCT02713282 |
PANSS total, change
- Clozapine
- —Not posted · NCT00649844
- Paliperidone palmitate (Invega Trinza)
- -1.8 vs -1.6vs PP3MNCT03345342
CGI-S, change
- Clozapine
- —Not posted · NCT00649844
- Paliperidone palmitate (Invega Trinza)
- 0 vs 0vs PP3MNCT03345342
2 other results
- -0.2 vs -0.3 NCT02431702
- -0.7 vs -0.7 NCT02431702
PANSS response
- Clozapine
- —Not posted · NCT00649844
- Paliperidone palmitate (Invega Trinza)
- —Not posted · NCT02713282
PSP, change
- Clozapine
- —Not posted · NCT00649844
- Paliperidone palmitate (Invega Trinza)
- 1 vs 1.1vs PP3MNCT03345342
2 other results
- 7.5 vs 7 NCT02431702
- 2.5 vs 2.9 NCT02431702
Relapse (% of patients)
- Clozapine
- —Not posted · NCT00649844
- Paliperidone palmitate (Invega Trinza)
- —Not posted · NCT02713282
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. Clozapine: 3 of 4 rows · Paliperidone palmitate (Invega Trinza): 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Clozapine | Paliperidone palmitate (Invega Trinza) |
|---|---|---|
| Dropout rate | 41.7%a NCT01639872 · Phase 4 · registry result, not featured evidence show 2 more results0% NCT00498550 · Phase 4 · registry result, not featured evidence 17.2% NCT02404155 · Phase na · registry result, not featured evidence | —Double-blind PP6Mb NCT03345342 · Phase 3 · Schizophrenia · phase 3 show 6 more results—Follow-up Phase PP6M NCT03345342 · Phase 3 · Schizophrenia · phase 3 13.5%700 or 1000 mg eq NCT04072575 · Phase 3 · combination — NCT01529515 · Phase 3 —Part 2-Paliperidone Palmitate (PP) NCT02431702 · Phase 3 · registry result, not featured evidence · combination —Part 3- OAP to PP (or Delayed-Star NCT02431702 · Phase 3 · registry result, not featured evidence —Part 3-PP to PP (Extended Disease NCT02431702 · Phase 3 · registry result, not featured evidence |
| Discontinued due to AEs | —a NCT01639872 · Phase 4 · registry result, not featured evidence show 2 more results— NCT00498550 · Phase 4 · registry result, not featured evidence — NCT02404155 · Phase na · registry result, not featured evidence | —Double-blind PP6Mb NCT03345342 · Phase 3 · Schizophrenia · phase 3 show 6 more results—Follow-up Phase PP6M NCT03345342 · Phase 3 · Schizophrenia · phase 3 3.9%700 or 1000 mg eq NCT04072575 · Phase 3 · combination — NCT01529515 · Phase 3 —Part 2-Paliperidone Palmitate (PP) NCT02431702 · Phase 3 · registry result, not featured evidence · combination —Part 3- OAP to PP (or Delayed-Star NCT02431702 · Phase 3 · registry result, not featured evidence —Part 3-PP to PP (Extended Disease NCT02431702 · Phase 3 · registry result, not featured evidence |
| Serious AEs | 13%a NCT01639872 · Phase 4 · registry result, not featured evidence show 2 more results26.7% NCT00498550 · Phase 4 · registry result, not featured evidence 6.9% NCT02404155 · Phase na · registry result, not featured evidence | 5%Double-blind PP6Mb NCT03345342 · Phase 3 · Schizophrenia · phase 3 show 6 more results5.5%Follow-up Phase PP6M NCT03345342 · Phase 3 · Schizophrenia · phase 3 4.5%700 or 1000 mg eq NCT04072575 · Phase 3 · combination 2.5% NCT01529515 · Phase 3 12.8%Part 2-Paliperidone Palmitate (PP) NCT02431702 · Phase 3 · registry result, not featured evidence · combination 5.3%Part 3- OAP to PP (or Delayed-Star NCT02431702 · Phase 3 · registry result, not featured evidence 2%Part 3-PP to PP (Extended Disease NCT02431702 · Phase 3 · registry result, not featured evidence |
| Most frequent reported AEs | a other-sialorrhea 43.5% weight gain 30.4% sedation 21.7% NCT01639872 · Phase 4 · registry result, not featured evidence show 2 more resultsgastrointestinal disorder - other: hypersalivation 66.7% somnolence 60% weight gain 40% NCT00498550 · Phase 4 · registry result, not featured evidence salivation 68.2% sedation 52.9% malaise 52.6% NCT02404155 · Phase na · registry result, not featured evidence | b weight increased 8.4% injection site pain 7.7% headache 6.7% NCT03345342 · Phase 3 · Schizophrenia · phase 3 show 6 more resultsnasopharyngitis 3.7% upper respiratory tract infection 0.9% headache 0% NCT03345342 · Phase 3 · Schizophrenia · phase 3 700 or 1000 mg eq headache 13.5% blood prolactin increased 10.7% hyperprolactinaemia 7.3% NCT04072575 · Phase 3 · combination headache 8.8% (placebo 4.1%) weight increased 8.8% (placebo 3.4%) anxiety 8.1% (placebo 10.3%) NCT01529515 · Phase 3 weight increased 28.2% akathisia 9% headache 9% NCT02431702 · Phase 3 · registry result, not featured evidence · combination weight increased 15.8% anxiety 10.5% insomnia 10.5% NCT02431702 · Phase 3 · registry result, not featured evidence weight increased 14.3% insomnia 10.2% nasopharyngitis 6.1% NCT02431702 · Phase 3 · registry result, not featured evidence |
Notes
- aPopulation comparability has not been reviewed for these studies.
- bPopulation comparability has not been reviewed for 5 of these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Clozapine
Paliperidone palmitate (Invega Trinza)
show 2 more results
show 2 more results
+ 11 further endpoints in the CSV export.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Clozapine's landscape · Paliperidone palmitate (Invega Trinza)'s landscape